Pfenex Appoints Dr. Robert Peach to Scientific Advisory Board
April 23 2019 - 8:05AM
Pfenex Inc. (NYSE American: PFNX), today announced the appointment
of Robert Peach, Ph.D. to the Pfenex Scientific Advisory Board.
“We are very excited to have Dr. Peach join our
Scientific Advisory Board and look forward to his insight and
contributions as we leverage our Pfēnex Expression Technology
platform to expand our development pipeline,” said Eef
Schimmelpennink, Chief Executive Officer of Pfenex. “As we advance
our current development pipeline and look forward to the potential
commercial launch of our first product in the U.S. as early as the
end of this year, we are increasing our focus on using our
proprietary platform technology to create new advanced protein
therapies.”
“I am looking forward to working with the
innovative team at Pfenex and the rest of the Scientific Advisory
Board on their efforts to expand their development pipeline
leveraging the Pfēnex Expression Technology platform. The Company’s
wide-ranging set of assets currently in development have
demonstrated the broad applications for the Pfēnex Expression
Technology platform, including the creation of potential
therapeutic equivalents, biologics, vaccines, and biosimilars,”
stated Dr. Peach.
Dr. Peach has over 25 years of drug discovery
and development experience in the pharmaceutical and biotechnology
industry. In 2009, he co-founded Receptos, becoming Chief
Scientific Officer and raised approximately $59 million in venture
capital and approximately $800 million in an IPO and three
subsequent follow-on offerings. In August 2015, Receptos was
acquired by Celgene for $7.8 billion. Dr. Peach has also held
senior executive and scientific positions in other companies,
including Apoptos, Biogen Idec, IDEC and Bristol-Myers Squibb,
supporting in-licensing, acquisition and venture investments.
His extensive drug discovery and development experience in
autoimmune and inflammatory diseases and cancer has resulted in
multiple drugs entering clinical trials and three registered
drugs. He currently serves on the Board of Directors of
Amplia Therapeutics, AdAlta and Avalia Immunotherapies and has been
a consultant for several other biotechnology companies. Dr. Peach
is the co-author of 76 scientific publications and book chapters,
and 26 patents. Dr. Peach earned his BS and MS (1st class
honors) from the University of Canterbury and a Ph.D. in
Biochemistry from the University of Otago, New Zealand.
About Pfenex Inc.Pfenex is a
clinical-stage development and licensing biotechnology company
focused on leveraging its Pfēnex Expression Technology® to develop
and improve protein therapies for unmet patient needs. Using the
patented Pfēnex Expression Technology platform, Pfenex has created
an advanced pipeline of potential therapeutic equivalents,
vaccines, biologics and biosimilars. Pfenex also uses its Pfēnex
Expression Technology platform to produce CRM197, a diphtheria
toxoid carrier protein used in prophylactic and therapeutic
vaccines. Pfenex’s lead product candidate is PF708, a therapeutic
equivalent candidate to Forteo® (teriparatide) for the treatment of
osteoporosis. In addition, Pfenex is developing hematology/oncology
products, including PF743, a recombinant crisantaspase, and PF745,
a recombinant crisantaspase with half-life extension technology, in
collaboration with Jazz Pharmaceuticals.
Pfenex investors and others should note that Pfenex
announces material information to the public about Pfenex through a
variety of means, including its website (http://www.pfenex.com/),
its investor relations website (http://pfenex.investorroom.com/),
press releases, SEC filings, public conference calls, corporate
Twitter account (https://twitter.com/pfenex), Facebook page
(https://www.facebook.com/Pfenex-Inc-105908276167776/timeline/),
and LinkedIn page (https://www.linkedin.com/company/pfenex-inc) in
order to achieve broad, non-exclusionary distribution of
information to the public and to comply with its disclosure
obligations under Regulation FD. Pfenex encourages its investors
and others to monitor and review the information Pfenex makes
public in these locations as such information could be deemed to be
material information. Please note that this list may be updated
from time to time.
Cautionary Note Regarding Forward-Looking
Statement
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements generally relate to
future events or Pfenex's future financial or operating
performance. In some cases, you can identify forward-looking
statements because they contain words such as "may," "will,"
"should," "expects," "plans," "anticipates," "could," "intends,"
"target," "projects," "contemplates," "believes," "estimates,"
"predicts," "potential" or "continue" or the negative of these
words or other similar terms or expressions that concern Pfenex's
future expectations, strategy, plans or intentions. Forward-looking
statements in this press release include, but are not limited to,
statements regarding the future potential of Pfenex's product
candidates and the company in general, including its belief in its
ability to expand and advance its development pipeline; Pfenex’s
ability to leverage its Pfēnex Expression Technology; the
possibility of the potential commercial US launch of PF708 as early
the end of this year; and the potential to develop additional
product candidates. Pfenex’s expectations and beliefs regarding
these matters may not materialize, and actual results in future
periods are subject to risks and uncertainties that could cause
actual results to differ materially from those projected. Actual
results may differ materially from those indicated by these
forward-looking statements as a result of the uncertainties
inherent in the clinical drug development process, including,
without limitation, Pfenex's ability to successfully demonstrate
the efficacy and safety of its product candidates; the pre-clinical
and clinical results for its product candidates, which may not
support further development of product candidates or may require
Pfenex to conduct additional clinical trials or modify ongoing
clinical trials or regulatory pathways; challenges related to
commencement, patient enrollment, completion, and analysis of
clinical trials; difficulties in achieving and demonstrating
biosimilarity in formulations; Pfenex's ability to manage operating
expenses; Pfenex's ability to obtain additional funding to support
its business activities and establish and maintain strategic
business alliances and new business initiatives; Pfenex's
dependence on third parties for development, manufacture,
marketing, sales and distribution of products; unexpected
expenditures; litigation and other proceedings regarding
intellectual property rights; and difficulties in obtaining and
maintaining intellectual property protection for its product
candidates. Information on these and additional risks,
uncertainties, and other information affecting Pfenex's business
and operating results is contained in Pfenex’s Annual Report on
Form10-K for the period ended December 31, 2018 filed with the
Securities and Exchange Commission and in its other filings with
the Securities and Exchange Commission. The forward-looking
statements in this press release are based on information available
to Pfenex as of the date hereof, and Pfenex disclaims any
obligation to update any forward-looking statements, except as
required by law.
Company Contact:Susan A. KnudsonChief Financial
Officer(858) 352-4324sknudson@pfenex.com
Pfenex (AMEX:PFNX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pfenex (AMEX:PFNX)
Historical Stock Chart
From Sep 2023 to Sep 2024